On Tuesday, June 16, 2015, Drs. Steve Shoptaw and Raphy Landovitz, from the CHIPTS Combination Prevention Core, delivered well-received plenaries at the HIV Prevention Trials Network (HPTN) Annual Meeting in Washington, DC. Dr. Shoptaw presented early in the order with a brief but comprehensive presentation on the topic of “Non-Injection Substance Use and HIV.” Dr. Landovitz closed out the afternoon of science with a tremendous presentation on “PrEP: Promising New Agents”.
Dr. Shoptaw is working with his colleagues in leadership at HPTN to bring focused attention to the contributions to the HIV epidemic made by people who use non-injection substances, including binge drinking. Dr. Landovitz is the Protocol Team Leader for HPTN 083, A Phase 2b/3 Double Blind Efficacy Study Of Quarterly Injectable Cabotegravir Compared to Daily Oral Tenofovir Disoproxil.
Congratulations to Drs. Shoptaw and Landovitz for representing UCLA.